Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 29, 2002

View Archived Issues

Potential use of botulinum toxin A in the treatment of wrist spasticity following stroke

Enhanced p53-specific T-cell immunity found in colorectal cancer patients treated with ALVAC-p53

Potential use of LFM-A13 against chemotherapy-resistant B cell lymphomas or leukemias

FDA accepts MethyPatch NDA

Allos Therapeutics examines potential of RSR-13 in locally advanced cervical cancer

ISAtx-247 is a more effective immunosuppressant than ciclosporin in cynomolgus monkeys

Renal vasoconstriction induced by tacrolimus in rats is prevented by low dose theophylline

Selective inhibition of Rho-associated protein kinase attenuates hepatic ischemia/reperfusion injury

Effects of bimosiamose on renal preservation injury in a canine transplant model

EP4 selective agonists for treatment of skeletal disorders reported by Pfizer

Berlex reports a new series of CCR1 antagonists at the recent ACS meeting

Aerosol tacrolimus prevents acute pulmonary allograft rejection in a rat lung allograft model

Merck Frosst describes a new series of potent PDE4 inhibitors

Pivotal program protocol for T-67 approved by FDA

Crucell and Johns Hopkins sign cooperative agreement for antibodies against LCH

E.U. approval for Aranesp

MedImmune responds to Flumist complete response letter

Subanalysis of SnET2 phase III data

Dyax initiates phase I/II trial of DX-88 in cardiopulmonary bypass patients

Potent and selective MMP inhibitors designed at Pharmacia

Scientists at Genzyme identify novel compounds that modulate TNF-alpha signaling

Muscarinic M3 receptor antagonists disclosed by Almirall Prodesfarma

Farnesyl protein transferase-inhibiting compounds claimed by Janssen

PPAR modulators for use as hypoglycemics and lipid-lowering agents

DPP-IV inhibitors with utility in type 2 diabetes and associated complications

Daiichi Pharmaceutical prepares CDK4 inhibitors